Weifa ASA operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Weifa ASA with three other
miscellaneous service companies in Europe:
of the United Kingdom
sales of £39.23 million [US$51.02 million]
of which 67%
was Clinical Research Service),
Karo Pharma AB
(347.26 million Swedish Kronor [US$42.13 million]
of which 100%
was Drugs Discovery & Dev), and
based in Germany
(49.74 million Euro [US$58.04 million]
of which 99%
was Partnered Discovery).
Weifa ASA reported sales of NOK 399.11 million (US$49.66 million)
December of 2016.
increase of 20.2%
versus 2015, when the company's sales were NOK 332.04 million.
This was the third consecutive year of growth at Weifa ASA.